DDrare: Database of Drug Development for Rare Diseases

( DrugBank: - / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
75	Cushing disease	205

75. Cushing disease

Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127

trials per page:

Showing 1 to 10 of 205 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04339751 (ClinicalTrials.gov)	March 22, 2023	8/4/2020	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Cushing's Disease	Drug: Vorinostat	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	22	Phase 2	United States
2	NCT04569591 (ClinicalTrials.gov)	March 22, 2023	29/9/2020	Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Cushing's Disease;Pituitary Adenoma	Drug: Acthrel	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	8 Years	N/A	All	22	N/A	United States
3	NCT05633953 (ClinicalTrials.gov)	December 2022	16/11/2022	Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome	A Retrospective Observational Study to Evaluate the Safety and Effectiveness of Osilodrostat for the ...	Cushing's Syndrome	Drug: Osilodrostat	RECORDATI GROUP	NULL	Not yet recruiting	18 Years	N/A	All	50		NULL
4	EUCTR2021-006184-19-BG (EUCTR)	22/06/2022	31/05/2022	Study of SPI-62 in Patients with Adrenocorticotropic Hormone-dependent Cushing’s Syndrome	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome	Cushing’s Syndrome <br>MedDRA version: 20.1;Level: PT;Classification code 10035109;Term: Pituitary-d ...	Product Name: SPI-62<br>Product Code: SPI-62<br>INN or Proposed INN: Not applicable<br>Other descrip ...	Sparrow Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes<br>Male: yes	26	Phase 2	United States;Romania;Bulgaria
5	NCT05436639 (ClinicalTrials.gov)	June 9, 2022	23/6/2022	SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	Autonomous Cortisol Secretion (ACS);ACTH-Independent Cushing Syndrome;ACTH-Independent Adrenal Cushi ...	Drug: SPI-62 dose1;Drug: SPI-62 dose 2;Drug: SPI-62 dose 3;Drug: SPI-62 dose 4;Drug: Placebo	Sparrow Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	150	Phase 2	United States;Bulgaria;France;Romania;United Kingdom;Germany;Italy
6	NCT05382156 (ClinicalTrials.gov)	June 2022	3/5/2022	Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome	A Non-interventional Study to Assess the Long-term Safety and Efficacy of Osilodrostat in Patients W ...	Endogenous Cushing's Syndrome	Drug: Osilodrostat	RECORDATI GROUP	NULL	Not yet recruiting	18 Years	N/A	All	100		NULL
7	NCT05347979 (ClinicalTrials.gov)	May 25, 2022	18/4/2022	Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran ...	An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Ph ...	Cushing Syndrome;Neoplasms	Drug: Dabigatran Etexilate;Drug: Relacorilant	Corcept Therapeutics	NULL	Completed	18 Years	55 Years	All	30	Phase 1	United States
8	EUCTR2018-001616-30-NL (EUCTR)	14/04/2022	12/10/2021	Extension of a clinical trial to assess the safety of a study drug called CORT125134 in the treatmen ...	An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Sig ...	Endogenous Cushing Syndrome <br>MedDRA version: 24.0;Level: LLT;Classification code 10011657;Term: C ...	Product Code: CORT125134<br>INN or Proposed INN: Relacorilant<br>Other descriptive name: (R)-(1-(4-F ...	Corcept Therapeutics Incorporated	NULL	Authorised-recruitment may be ongoing or finished			Female: yes<br>Male: yes	75	Phase 2;Phase 3	United States;Hungary;Canada;Spain;Poland;Romania;Austria;Bulgaria;Israel;Germany;Netherlands;Italy
9	JPRN-jRCT1021210011	13/04/2022	13/04/2022	A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and Alprazolam	A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and anxiolytic Alprazolam	Pseudo Cushing's Syndrome <br>Glucocorticoid , Stress, dexamethasone suppression test;D003480	In patients suspected of having Cushing's syndrome or pseudo-Cushing's syndrome, we perform two load ...	Asari Yuko	NULL	Recruiting	Not applicable	Not applicable	Both	20	Phase 2	Japan
10	NCT05307328 (ClinicalTrials.gov)	March 1, 2022	23/3/2022	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome	SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome	Cushing's Syndrome I;Cushing Disease Due to Increased ACTH Secretion;Cortisol Excess;Cortisol; Hyper ...	Drug: SPI-62;Drug: Placebo	Sparrow Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	26	Phase 2	Romania;Bulgaria;United States

First Previous1 2 3 4 5…21Next Last